MedTrace Logo

Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism

NCT02192749 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-10-13

No results posted yet for this study

Summary

Allogeneic (not from the subject) human umbilical cord tissue-derived stem cells administered intravenously (IV) in a series of 4 infusions every 3 months over the course of one year is safe and will induce a therapeutic effect in autism patients.

Conditions

Interventions

BIOLOGICAL

Umbilical cord mesenchymal stem cells

Sponsors & Collaborators

  • Translational Biosciences

    lead INDUSTRY

Principal Investigators

  • Nelson Novarro, MD

  • Jorge Paz-Rodriguez, MD · Translational Biosciences / Stem Cell Institute Panama

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2017-08-31
Completion
2017-08-31

Countries

  • Panama

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02192749 on ClinicalTrials.gov